Market Performance - The A-share market has shown a strong rebound since the second quarter of this year, with the Shanghai Composite Index rising over 1% to 3825.76 points, marking its first time above 3800 points in nearly a decade [2] - The total trading volume across Shanghai, Shenzhen, and Beijing reached 2.58 trillion yuan on August 22, 2025, with the Shanghai Composite Index increasing nearly 14% since its low on April 7 [2] Fund Performance - Active equity funds have demonstrated significant profitability this year, with the Wind index showing that the ordinary stock fund index and the mixed equity fund index have increased by 24.96% and 24.72% respectively since the beginning of the year [2] - A total of 22 active equity funds have doubled their net value year-to-date, with the leading fund, Changcheng Medical Industry Select A, achieving a net value growth rate of 130.76% [3] Fund Management Insights - Among the 40 active equity funds that have seen a cumulative net value decline of over 50% since inception, they are managed by 24 different fund management companies, including prominent names like GF Fund and Dongfang Alpha Fund [4] - GF Fund has the highest number of funds with over 50% net value decline, with six funds including GF Chengxiang A/C and GF Youxian Growth A/C [5][11] Fund Manager Performance - The performance of certain fund managers has been notably poor, with multiple funds under their management reporting significant losses. For instance, the Taiping Flexible Allocation Fund has reported negative returns in six out of nine years from 2016 to 2024 [6][8] - The current fund manager of Morgan Integration Driven A has also faced challenges, with a cumulative net value return of -54.04% since its inception [9][10] Fund Launch Trends - The year 2021 saw a peak in new fund launches, with GF Fund issuing 67 new funds, raising nearly 210 billion yuan. However, the number of new fund launches has significantly decreased in subsequent years [13][14] - The trend of launching funds during market peaks has led to a high number of funds experiencing substantial losses, with over half of the funds that have seen a net value decline of over 50% being established during the last bull market in 2021 [11]

Core Insights - The Shanghai Composite Index has surpassed last year's "9.24" high point, reaching a nearly four-year high, with 160 funds doubling since last year [2] - There have been 12 funds that have doubled in value this year, focusing primarily on innovative pharmaceuticals [2][5] Fund Performance Summary - The top-performing funds this year include: - Huatai-PineBridge Hong Kong Advantage Selection A: 132.55% return, managed by Zhang Lian, with a scale of 2.194 billion [3] - Great Wall Pharmaceutical Industry Selection A: 128.53% return, managed by Liang Furui, with a scale of 11.317 billion [3] - Yongying Technology Smart Selection A: 119.80% return, managed by Ren Jie, with a scale of 11.665 billion [3] - Bank of China Hong Kong Stock Connect Pharmaceutical A: 116.19% return, managed by Zheng Ning, with a scale of 7.404 billion [3] - Yongying Pharmaceutical Innovation Smart Selection A: 112.33% return, managed by Shan Lin, with a scale of 30.428 billion [3] - Other notable funds include Huashan Pharmaceutical Biology A and various Hong Kong Stock Connect Innovative Pharmaceutical ETFs, all showing significant returns [3] Investment Themes - Among the doubling funds, 11 are heavily invested in innovative pharmaceuticals, indicating a strong trend towards this sector [5] - The Huatai-PineBridge Hong Kong Advantage Selection fund has emerged as the top performer with over 132% return, highlighting the success of innovative pharmaceutical themes [5]

Core Viewpoint - The market has seen significant recovery, with the Shanghai Composite Index breaking the previous high from September 2022, indicating a bullish trend in the equity market [1][6]. Group 1: Market Performance - As of August 13, 2023, 160 funds have doubled in value since the September 2022 peak, with 12 funds achieving this milestone in 2023 alone [1][6]. - The "Wande Equity Mixed Fund Index" has risen by 19.67% this year, and since the September 2022 rally, it has increased by 43.18% [6][8]. - The Hang Seng Innovation Drug Index has surged by 109% this year, while the Wande Innovation Drug Index has increased by 51% [13]. Group 2: Fund Recovery and Redemption - Research indicates that the average return of new funds launched between 2019 and 2021 has returned to break-even, while existing funds from the previous bull market show an average loss of 5% [8][9]. - Despite the recovery, there is significant redemption pressure on equity funds, with a 56.43% increase in net redemptions for active equity funds in Q2 2025 [10]. - Investors are showing a tendency to redeem funds once they reach break-even, reflecting a lack of confidence in long-term returns [10][11]. Group 3: Sector Focus and Fund Management - Funds heavily invested in innovative sectors such as pharmaceuticals, AI, and robotics have generally maintained their positions, with few making significant adjustments [1][12]. - The majority of funds focused on innovation sectors have not reduced their holdings, despite some individual fund managers considering adjustments due to high valuations [13][14]. - There is a notable trend of funds shifting towards fixed-income products, with 50% to 70% of monthly sales in certain banks being allocated to these products [1][11].

Core Insights - The Shanghai Composite Index has recently surpassed the previous high from September 24, 2022, reaching a nearly four-year peak [1] - As of August 13, 2023, the market has seen 160 funds double in value since the last high, with 12 funds achieving this feat in 2023 alone [2][4] - The active equity funds have shown a rapid recovery in net value, with the "equity mixed fund index" rising by 19.67% this year and 43.18% since the last high [6][8] Fund Performance - The top-performing funds this year are heavily invested in innovative pharmaceuticals, AI, humanoid robots, and computing power, with the best performer, Huatai-PB Hang Seng Innovation Drug ETF, achieving over 132% returns [4][12] - A total of 219 funds have reported returns between 50% and 100% this year, primarily in sectors like pharmaceuticals, technology, and new consumption [5][6] Redemption Trends - Despite the recovery, many funds are facing significant redemption pressure, particularly those heavily invested in electric new energy, pharmaceuticals, and food and beverage sectors [10] - The redemption trend has not reversed, with a notable increase in net redemptions for equity funds, indicating a lack of confidence among investors despite some funds returning to profitability [9][10] Market Sentiment - There are signs of a potential reversal in the "return kill" phenomenon, with some investors returning to the market as they see positive returns [11] - The current market atmosphere is optimistic, with institutional clients continuing to subscribe to rights-containing products [11] Sector Focus - The innovation drug sector has been a major winner, with the Hang Seng Innovation Drug Index rising by 109% this year [12] - Fund managers have largely maintained their positions in high-performing sectors like AI and computing power, although some are considering reducing exposure to certain high-valuation stocks [18]

Core Insights - The active management equity funds are experiencing a strong recovery in returns, with 95% achieving positive returns and an average return exceeding 15% as of August 7, 2025 [1][2] - The pharmaceutical sector has emerged as the biggest winner, with four funds doubling their returns, all focused on this industry [3] Fund Performance - As of August 7, 2025, the average return for over 4,500 active equity funds is 15.03%, while more than 93% of over 2,500 stock index funds have positive returns averaging 11.8% [2] - Active equity funds have outperformed major indices like CSI 300 (4.6%) and CSI 500 (10.6%) after three years of underperformance [2] Fund Manager Dynamics - There are 90 active equity fund managers managing over 10 billion yuan, with Zhang Kun from E Fund leading at over 50 billion yuan [5][6] - Among these managers, 86 have achieved positive returns, with the average return for those managing over 30 billion yuan being 9.8%, which is lower than the average of the top 90 managers [6] Sector Focus - The four funds that doubled their returns are primarily invested in the pharmaceutical sector, including Changcheng Pharmaceutical Industry Selection and Huashan Pharmaceutical Biotechnology [3] - The top-performing managers, Zhang Wei and Zhang Lu, have focused on themes like innovative drugs and robotics, contributing to their high returns of 65.8% and 53.4% respectively [8] Underperforming Funds - Despite the overall positive trend, 228 active equity funds reported negative returns, with the worst performer, Qianhai Kaiyuan AI A, showing a return of -18.5% [3] - Wang Mingxu from GF Fund has seen 7 out of 8 funds underperform, with a bottom return of -7.4% [8][9] Investor Sentiment - Although the A-share market has been rising, investor confidence in active equity funds remains low, with a significant reduction in total shares of active equity funds by approximately 198.24 billion shares in the first half of 2025 [3]

Core Viewpoint - The public fund industry is experiencing a significant recovery in 2025 after a four-year downturn, with over 90% of active equity funds achieving positive returns this year, leading to increased confidence among fund managers and a revival in fund issuance [1][2]. Fund Performance - Active equity funds have seen an average return of over 13% year-to-date as of August 1, with a notable number of funds doubling their performance, including 17 funds that achieved over 140% returns [2]. - More than 800 active equity funds reached historical net asset value highs in the past month, indicating a strong recovery from previous losses [3]. Market Dynamics - The current market environment presents structural opportunities in sectors like humanoid robots, AI hardware, and innovative pharmaceuticals, which have contributed to the recovery of fund performance [2]. - Fund managers are increasingly focusing on high-growth sectors, with a shift from traditional sectors like real estate and bonds to equities, particularly in new economy sectors [3]. Fund Manager Behavior - Fund managers are showing a clear increase in risk appetite, with many raising their stock positions and concentrating their holdings in core stocks [5]. - Data shows that nearly 2,500 funds increased their stock positions and concentration in the second quarter, reflecting a significant shift in risk preference [5]. Fund Issuance Trends - The pace of new fund issuance has accelerated, with 149 new funds launched in July, matching the issuance rate from November 2022 [11]. - Notable funds like Dachen Insight Advantage raised 2.461 billion yuan in just eight days, marking the largest initial fundraising for active equity funds this year [9]. Investor Sentiment - Despite the positive performance, many investors remain cautious, with a tendency to redeem funds once they break even, indicating a need for trust rebuilding in active equity funds [1][11]. - The market is witnessing a preference for passive investment products over active equity funds, with high-performance products gaining more attention [11].

Core Viewpoint - The public fund industry is experiencing a significant recovery in 2025 after a four-year downturn, with over 90% of active equity funds achieving positive returns this year, leading to increased confidence among fund managers and a revival in fund issuance [1][3]. Fund Performance - Active equity funds have seen an average return of over 13% year-to-date, with a notable number of funds doubling their performance, including 17 funds that achieved over 140% returns as of July 29 [3]. - Despite some funds still recovering from previous losses, the short-term performance rebound is expected to support long-term growth [3]. - More than 800 active equity funds reached historical net asset value highs in the past month, indicating a strong recovery [3]. Fund Manager Sentiment - Fund managers are showing increased risk appetite, with many raising stock positions and focusing on core holdings [7][8]. - A significant number of funds have increased their stock positions by 5 to 8 percentage points, particularly in technology and growth sectors, as they anticipate improving profit growth in the latter half of the year [8][10]. Fund Issuance Trends - The positive performance has led to a noticeable acceleration in the issuance of new funds, particularly equity funds, with a significant increase in marketing efforts [12]. - In June, 155 new funds were established, marking a near-record high, and 135 funds were launched in July, indicating a robust recovery in the fund issuance market [13]. - Fund companies are rapidly increasing the pace of new fund launches to capitalize on the market rebound, with 149 new funds initiated in July alone [13]. Investor Behavior - Despite the positive performance, many investors remain cautious, with a tendency to redeem funds once they break even, indicating a trust gap that needs to be addressed for sustained growth [1][14]. - The demand for passive investment products is currently outpacing that for active equity funds, with high-performance products attracting more interest than stable ones [14].

21世纪经济报道记者 黎雨辰 伴随市场行情的持续回暖，一批主动权益基金的净值继续上涨。 数据显示，今年以来（截至8月1日，下同），上证指数上涨6.21%，沪深300指数上涨3.05%，创业板指 上涨8.45%。表现更好的港股市场，恒生指数涨幅达到了22.17%。 易方达先锋成长的基金经理武阳就重点提及，其在今年二季度重点聚焦科技（AI、半导体）、高端制 造、消费及医疗健康。其在操作上一个重要的特征就是降低自动驾驶/机器人配置，转向确定性更高的 创新药、TMT修复及新消费领域。 这也带来了公募基金连续第三个盈利的季度。天相投顾数据显示，2025年二季度，公募基金产品盈利 3850.98亿元。这背后是今年二季度市场行情的持续走高，其中上证指数上涨 3.26%，沪深 300 指数上 涨 1.25%，创业板综合指数上涨 5.80%。 据21世纪经济报道记者统计，权益基金（包括股票型基金和混合型基金）近一年来（截至8月3日，下 同），收益翻倍的基金（分份额统计）已经有72只。 从基金管理人来看，按照天相投顾数据，二季度纳入统计的162家基金管理人中，有150家公司旗下基金 整体实现盈利，其中更有11家公司旗下基金整体盈 ...

Group 1 - The core viewpoint of the articles highlights a divergence in performance between actively managed equity funds and ETFs, where actively managed funds have outperformed in terms of returns, but ETFs have seen greater growth in scale [1][2][3] - The innovation drug sector has driven significant performance for both actively managed funds and ETFs, with a notable number of funds achieving double returns this year, particularly in the innovation drug theme [2][3] - Despite strong performance, actively managed funds have not attracted as much capital as ETFs, which have expanded significantly in scale, particularly in response to high-performing sectors like innovation drugs and humanoid robots [3][4] Group 2 - Data shows that 10 actively managed innovation drug funds had a total scale of only 9.4 billion yuan at the end of Q2, with a modest increase of 5.8 billion yuan during the quarter, while 7 ETFs saw an increase of 12.9 billion yuan, reaching a total scale of 28.4 billion yuan [3] - The rapid growth of ETFs is attributed to their passive tracking mechanism, which allows them to capture industry beta returns effectively, leading investors to prefer ETFs for quick exposure to high-growth sectors [4][5] - The management fees for ETFs are generally lower than those for actively managed funds, providing a cost and efficiency advantage that attracts investors, especially when returns are comparable [6][7] Group 3 - The increasing popularity of ETFs has pressured actively managed funds, as the latter struggle to attract new capital despite their strong performance, with many investors favoring the transparency and flexibility of ETFs [5][6] - The shift in focus towards passive investment strategies by fund companies further constrains the space for actively managed funds, as new ETF products are increasingly being launched in high-demand sectors [6][7] - The current trend indicates that ETFs are more appealing to investors compared to actively managed funds, prompting the latter to seek differentiated strategies for survival [7]

Core Viewpoint - The public fund industry is experiencing a resurgence in 2025 after a prolonged period of stagnation, with over 90% of actively managed equity funds achieving positive returns this year, indicating a potential recovery in investor confidence [1][2]. Group 1: Fund Performance - Active equity funds have seen an average return exceeding 13% year-to-date, with a significant number of products doubling their performance, including 17 funds achieving returns over 140% as of July 29 [2]. - Over 800 active equity funds reached historical net asset value highs in the past month, reflecting a strong recovery in short-term performance [2][3]. - Despite some funds still recovering from previous losses, the overall performance improvement is expected to support long-term growth [2]. Group 2: Fund Manager Sentiment - Fund managers are increasingly optimistic, raising stock positions and focusing on core holdings, with some increasing their stock allocations by 5 to 8 percentage points [5][6]. - A notable shift in investment strategy is observed, with managers concentrating their portfolios, as seen in the increase of top ten holdings' concentration from around 50% to nearly 60% [6][7]. - Fund managers are favoring sectors with clear growth potential, particularly in technology and high-end manufacturing, as they anticipate improving profit growth in the latter half of the year [5][7]. Group 3: Fund Issuance and Market Dynamics - The positive performance of funds has led to a noticeable increase in the pace of new fund issuance, particularly in equity funds, with a significant rise in marketing efforts [8][9]. - In June, 155 new funds were established, marking a near-record high, with July seeing 135 new fund launches, indicating a robust recovery in the fund issuance market [9][10]. - Despite the overall positive trend, not all funds are equally favored, with passive investment products gaining more traction than actively managed equity funds [10].